A Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine

Similar documents
Determination of Unbound Urinary Amino Acids Incorporated with Creatinine Normalization by LC-MS/MS Method with CLAM-2000 Online Sample Pre-treatment

Integration of steroids analysis in serum using LC-MS/MS with full-automated sample preparation

Fully Automated Online Sample Preparation AND Quantification of Amiodarone from Whole Blood using CLAM-LC-MS/MS

Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis of Basic Drugs

A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS

Fully automated sensitive determination of immunosuppressant drugs in whole blood, using high quality internal standardization

Quantitative Analysis of Carbohydrates and Artificial Sweeteners in Food Samples Using GFC- MS with APCI Interface and Post-column Reagent Addition

LCMS Vitamin D3 Method development

Modernizing the Forensic Lab with LC-MS/MS Technology

A FORENSIC TOXICOLOGY METHOD FOR THE DETERMINATION OF DESOMORPHINE, HEROIN, METHADONE, BUPRENORPHINE AND METABOLITES IN URINE USING LC/MS QQQ

Rapid Analysis of Water-Soluble Vitamins in Infant Formula by Standard-Addition

LCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching

A Robustness Study for the Agilent 6470 LC-MS/MS Mass Spectrometer

Quantitative Determination of Drugs of Abuse in Human Plasma and Serum by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup

Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids

Highly sensitive simultaneous quantitative analysis of estrone and equilin from plasma using LC/MS/MS

Vitamin D Metabolite Analysis in Biological Samples Using Agilent Captiva EMR Lipid

[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

Vitamin D3 and related compounds by ESI and APCI

Workflow for Screening and Quantification of the SAMHSA (NIDA) Panel in Urine Using UHPLC-TOF

Quantitative Analysis of Opiates in Urine Using RRHT LC/MS/MS. Application. Authors. Introduction. Abstract. Forensics

All stocks and calibration levels were prepared in water: methanol (50:50) v/v to cover range of all steroid concentrations (refer Table 1).

Overcoming the Challenges of Sample Preparation and LC/MS/MS Method Development for Clinical Applications

Analysis of drugs of abuse in biological matrix using Time of Flight technology

Quantitative Determination of Drugs of Abuse in Human Whole Blood by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup

A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography

Determination of 6-Chloropicolinic Acid (6-CPA) in Crops by Liquid Chromatography with Tandem Mass Spectrometry Detection. EPL-BAS Method No.

Protein Precipitation for Biological Fluid Samples Using Agilent Captiva EMR Lipid 96-Well Plates

4.5 Minute Analysis of Benzodiazepines in Urine and Whole Blood Using LC/MS/MS and an Ultra Biphenyl Column

Validation of an Automated Method to Remove

Direct Analysis of Urinary Opioids and Metabolites by Mixed-Mode µelution SPE Combined with UPLC/MS/MS for Forensic Toxicology

A Novel Solution for Vitamin K₁ and K₂ Analysis in Human Plasma by LC-MS/MS

Phospholipid characterization by a TQ-MS data based identification scheme

Shuguang Li, Jason Anspach, Sky Countryman, and Erica Pike Phenomenex, Inc., 411 Madrid Ave., Torrance, CA USA PO _W

Advancing your Forensic Toxicology Analyses; Adopting the Latest in Mass Spectrometry Innovations

Development of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid

Workflow for Screening and Quantification of the SAMHSA (NIDA) Panel in Serum Using UHPLC-TOF

Dr. Erin E. Chambers Waters Corporation. Presented by Dr. Diego Rodriguez Cabaleiro Waters Europe Waters Corporation 1

High Throughput Extraction of Opiates from Urine and Analysis by GC/MS or LC/MS/MS)

Determination of Amantadine Residues in Chicken by LCMS-8040

Reduced Ion Suppression and Improved LC/MS Sensitivity with Agilent Bond Elut Plexa

Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1

Matrix Factor Determination with the Waters Regulated Bioanalysis System Solution

Analysis of anti-epileptic drugs in human serum using an Agilent Ultivo LC/TQ

Extraction of a Comprehensive Steroid Panel from Human Serum Using ISOLUTE. SLE+ Prior to LC/MS-MS Analysis

Amphetamines, Phentermine, and Designer Stimulant Quantitation Using an Agilent 6430 LC/MS/MS

LC-MS/MS analysis of Chlorates in Milk and Whey Powder using the Agilent 6470 QQQ

Fast and simultaneous analysis of ethanol metabolites and barbiturates using the QTRAP 4500 LC-MS/MS system

Fast and easy separation of 23 drugs of abuse. including high, stable resolution of isobaric opioids from human urine by UHPLC-MS/MS

Comprehensive Forensic Toxicology Screening in Serum using On-Line SPE LC-MS/MS

Quantitative Analysis of Drugs of Abuse in Urine using UHPLC Coupled to Accurate Mass AxION 2 TOF Mass Spectrometer

High-Throughput, Cost-Efficient LC-MS/MS Forensic Method for Measuring Buprenorphine and Norbuprenorphine in Urine

E XCEL LENCE JUST GOT BETTER UCT FORENSICS CLEAN SCREEN XCEL SPE COLUMNS

O O H. Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL. LC /MS conditions

Quantitative Analysis of Amphetamine-Type Drugs by Extractive Benzoylation and LC/MS/MS. Application. Introduction. Authors. Abstract.

Rapid and Accurate LC-MS/MS Analysis of Nicotine and Related Compounds in Urine Using Raptor Biphenyl LC Columns and MS-Friendly Mobile Phases

Analysis of Rosuvastatin in Dried Blood Spot and Plasma Using ACQUITY UPLC with 2D Technology

Performance of an ultra low elution volume 96-well plate

Application Note LCMS-108 Quantitation of benzodiazepines and Z-drugs in serum with the EVOQ TM LC triple quadrupole mass spectrometer

Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis of Basic Drugs. Table 1. List of pain panel drugs

LC/MS/MS Analysis of Metabolites of Synthetic Cannabinoids JWH-018 and JWH-073 in Urine

SPE-LC-MS/MS Method for the Determination of Nicotine, Cotinine, and Trans-3-hydroxycotinine in Urine

Determination of Selected Illegal Drugs and its Important Metabolites in Waste Water by Large Volume Direct Injection HPLC-MS/MS

The Development of LC/MS Methods for Determination of MDMA (Ecstasy) and Metabolites in Biological Samples

METHAMPHETAMINE & AMPHETAMINE

Abstract. Introduction

Confirmation by Triple Quadrupole LC/MS/MS for HHS-compliant Workplace Urine Drug Testing

Extraction of Aflatoxin M1 From Infant Formula Using ISOLUTE Myco SPE Columns prior to LC-MS/MS Analysis

Analyze Barbiturates in Urine with Agilent 6430 LC/MS/MS and Poroshell 120 EC-C18

Paul D. Rainville Ph.D. Health Sciences Group Waters Corporation Waters Corporation 1

Dienes Derivatization MaxSpec Kit

Rapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System

Determination of Aflatoxins in Food by LC/MS/MS. Application. Authors. Abstract. Experimental. Introduction. Food Safety

Ultra-Fast Forensic Toxicological Screening and Quantitation under 3 Minutes using SCIEX X500R QTOF System and SCIEX OS 1.

Extraction of Multiple Mycotoxins From Grain Using ISOLUTE Myco prior to LC-MS/MS Analysis

Determination of Amphetamine and Derivatives in Urine

SWATH Acquisition Enables the Ultra-Fast and Accurate Determination of Novel Synthetic Opioids

Quantitation by High Resolution Mass Spectrometry: Case Study of TOF MS for the Quantitation of Allopurinol from Human Plasma

Extraction of Multiple Mycotoxins From Nuts Using ISOLUTE Myco prior to LC-MS/MS Analysis

The Development of LC/MS Methods for Determination of Polar Drugs of Abuse in Biological Samples

Comprehensive Two-Dimensional HPLC and Informative Data Processing for Pharmaceuticals and Lipids

Author. Introduction. Abstract

Quantitative Analysis of THC and Main Metabolites in Whole Blood Using Tandem Mass Spectrometry and Automated Online Sample Preparation

Comprehensive Study of SLE as a Sample. Preparation Tool for Bioanalysis

Off-line supercritical fluid extraction/gas chromatography-mass spectrometry analysis of pesticides in fish

Application Note. Author. Abstract. Introduction. Food Safety

Extraction of 25-hydroxy Vitamin D from Serum Using ISOLUTE. PLD+ Prior to LC-MS/MS Analysis

A NOVEL METHOD OF M/Z DRIFT CORRECTION FOR OA-TOF MASS SPECTROMETERS BASED ON CONSTRUCTION OF LIBRARIES OF MATRIX COMPONENTS.

One Source Toxicology Laboratory, 1213 Genoa Red Bluff, Pasadena, Texas 77504

LC/MS/MS of Trichothecenes and Zearalenone in Wheat Using Different Sample Prep Methods

Rapid Lipid Profiling of Serum by Reverse Phase UPLC-Tandem Quadrupole MS

Analysis of Pesticides (II) Metribuzin & their metabolites in Rice Jun Yonekubo, Nihon Waters, JAPAN

Analysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research

Mycotoxin Analysis in Peanut Butter Using Captiva EMR Lipid Cleanup and LC/MS/MS

NeoSal Oral Fluid Collection System Solutions for Forensic Drug Detection

Providing a Universal, One-step Alternative to Liquid-Liquid Extraction in Bioanalysis

Analysis of Cholesterol-Lowering Drugs (Statins) Using Dried Matrix Spot Technology

Methods and Materials

Transcription:

PO-CON737E A Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine ASMS 7 WP 353 Shao Hua Chia ; Zhi Wei Edwin Ting ; Daisuke Kawakami ; Jie Xing ; Zhaoqi Zhan Shimadzu (Asia Pacific) Pte Ltd, Singapore; Shimadzu Corporation, Kyoto

Introduction In recent years, LC/MS/MS methods are adopted in analyses of illicit and prescription drugs in toxicological samples such as urine and serum. Sample pre-treatment is always a critical step in the whole analysis procedure and on-line sample pre-treatment is desired not only for improving analysis throughput, but also minimizing human errors. The CLAM- module is designed for on-line sample pre-treatment in high throughput LC/MS/MS analysis of drugs and metabolites in biological samples such as plasma/serum and urine. Many sample preparation process can be performed automatically such as dispensing solvents, sample-reagent mixing by vortexing, sample filtering by vacuum filtration, and sample derivatisation with heating. Internal standard and reagent for derivatization or other purposes can be added to a sample before or after protein crash. We describe development of an automated sample pre-treatment using a Shimadzu CLAM- module coupled with Shimadzu LCMS-84 TQ system. It involves IS addition, protein precipitation, filtration and transferring the final solution to LC/MS/MS for analysis. This new platform was applied and evaluated for quantitation of 8 illicit drugs with 4 isotope-labelled internal standards (IS). Sample pipetting Reagent Pipetting Shaking Filtration Sample Transfer Samples are transferred to LC/MS/MS Figure : Procedure of protein crash and spiked-sample preparation Experimental Sample preparation and analytical conditions A total of 8 illicit drugs and 4 isotope-labeled internal standards (except for phencyclidine, methaqualone, methadone and propoxyphene) were used for setting up the MRM quantitation method. The urine samples, internal standards mixed solution and organic solvents were pre-loaded onto the CLAM-. An automated batch-run program allows sample pre-treatment and analysis to perform concurrently on the CLAM-LC-MS/MS platform. Table shows the analytical conditions on LCMS-84. Figure illustrates the automated workflow on the CLAM- module. An aliquot of ul of urine sample was dispensed into a filtration vial. Then, µl of mixed internal standard (IS) stock solution was added to the sample, followed by addition of 4 µl of organic solvent (MeOH : ACN = : in volume). The sample mixture was vortexed and filtered into a collection vial before injecting to LCMS-84. A Phenomenex Biphenyl column ( x. mm I.D.,.6µm) was used for the analysis of 8 analytes and 4 IS with a gradient elution program of minutes. A calibration series of spiked standard samples in urines were prepared in concentrations of, 5 and ng/ml. The concentration of each IS was ng/ml. A LCMS-84 with ESI was employed in this work.

Table : Analytical conditions on LCMS-84 Column : Biphenyl.6µ, A ( mml x.mm I.D.) Mobile Phase : A: Water with.% FA B: Methanol with.% FA Elution Program : Gradient elution ( minutes) B: 3% ( to.5 min) 9% (5.5 to 7. min) 3% (7.5 to min) Flow Rate :.4 ml/min Oven Temp. : 4ºC Injection : 5 µl Interface : ESI MS Mode : MRM, Positive Block Temp. : 4ºC DL Temp. : 5ºC CID Gas : Ar, 7 kpa Nebulizing Gas : N,. L/min Drying Gas : N, 5. L/min MeOH wetting (conditioning) Add ul of Sample (urine) Add ul of I.S. Add 4uL of ACN/MeOH Vortex for 6sec Vacuum Filter for 9sec Transferring to LC/MS/MS Figure : Typical auto-workflow of urine sample via protein-crash and adding IS for LC/MS/MS by CLAM- 3

Results and Discussion MRM-based method for eighteen illicit drugs Table shows the summarized results of optimized MRM transitions and parameters of the eighteen analytes and fourteen isotope-labelled internal standards (IS). However, four isotope-labelled ISs were not available. Three MRM transitions were selected for each compound except PROP with one as the quantitation ion and the other two for confirmation. A gradient elution program was optimized with a total runtime of eleven minutes. The MRM chromatograms of a mixed standard sample in urine are shown in Figure 3.. (x,) :96.>5.(+) :96.>.(+) :96.>65.5(+).5 Nimetazepam (x,) 3. 4:38.>5.5(+) 4:38.>.(+) 4:38.>7.5(+) Ketamine. (x,) 5:4.>5.5(+) 5:4.>7.5(+). 5:4.>79.(+) Norketamine (x,) 4. 3:468.3>55.5(+) 3:468.3>396.3(+) 3. 3:468.3>44.35(+) NIME KET NORKET BU. Buprenorphine 5. 6. 7. 8.. (x,) 4:44.>.(+) 4:44.>83.(+) 4:44.>87.(+).5 Norbuprenorphine 3. 4. 5. 6. (x,) 7:86.>.9(+) 7:86.>5.85(+) 7:86.>64.9(+) 5..5 Morphine 3. 4. 5. 6. 3. (x,) 8:3.>64.85(+) 8:3.>4.9(+) 8:3.>5.8(+). Codeine 4. 5. 6. 7. (x,) :38.>64.9(+) :38.>.9(+) 5. :38.>9.85(+) NORBU MORP COD 6-MAM.5 MAM 3. 4. 5. 6. (x,). 3:9.>68.(+) 3:9.>5.(+) 3:9.>77.(+).5 Benzoylecgonine (BE). 3. 4. (x,,) 4:44.3>86.(+) 4:44.3>59.5(+) 4:44.3>9.5(+).75.5.5 Phencyclidine (PCP). 3. 4. 5. (x,) 5:5.>3.5(+) 4. 5:5.>9.5(+) 5:5.>65.(+) 3.. Methaqualone. 3. 4. 5. (x,,) 6:3.>65.5(+) 6:3.>5.(+) 6:3.>77.(+) BE PCP METQ METD.5 Methadone 3. 4. 5. 6. (x,) 7:36.3>95(+). 7:36.3>9.(+) 7:36.3>65.(+) AMPH.5 Amphetamine 4. 5. 6. 7. (x,) 8:8.3>63.(+) 3. 8:8.3>5.5(+) 8:8.3>35.(+) MDEA. MDEA 4. 5. 6. 7. (x,) 9:8.3>63.(+) 9:8.3>35.5(+) 9:8.3>79.(+).5 MDA MDA 4. 5. 6. 7. (x,) 3:94.>63.5(+) 4. 3:94.>5.(+) 3:94.>33.(+) 3... 3. 4. 5. (x,) 7.5 3:34.>58.5(+) 3:34.>66.3(+) 5..5 Propoxyphene PROP. 3. 4. 5. (x,) 3:5.3>9.5(+) 3. 3:5.3>65.(+) 3:5.3>9.(+). Methamphetamine METH. 3. 4. 5.. 3. 4. 5. 4. 5. 6. 7.. 3. 4. 5. Figure 3: Individual MRM chromatograms of eighteen illicit drugs each ( ng/ml) and fourteen ISs ( ng/ml) spiked in urine obtained on CLAM-LC/MS/MS platform. 4

Table : MRM transitions and parameters of the illicit drugs on LCMS-86 Standard Internal Standard Compd. R.T (min) MRM (m/z) CE (V) Compd. R.T (min) MRM (m/z) CE (V) Nimetazepam (NIME) Ketamine (KET) Norketamine (NORKET) Buprenorphine (BU) Norbuprenorphine (NORBU) Morphine (MORP) Codeine (COD) 6-MAM Benzoylecgonine (BE) Phencyclidine (PCP) Methaqualone (METQ) Methadone (METD) Propoxyphene (PROP) Amphetamine (AMPH) MDEA MDA Methamphetamine (METH) 6.53 4.334 4.5 5.9 4.6.663 3.474 3.475 4.6 5.4 5.786 5.63 5. 3. 3.99 3.44 3.678 3.43 96.>5. 96.>. 96.>65. 38.>5. 38.>. 38.>7. 4.>5. 4.>7. 4.>79. 468.3>55. 468.3>44.4 468.3>396.3 44.>83. 44.>. 44.>87. 86.>.9 86.>5.9 86.>64.9 3.>64.9 3.>4.9 3.>5.8 38.>64.9 38.>.9 38.>9.9 9.>68. 9.>5. 9.>77. 44.3>86. 44.3>59.3 44.3>9. 5.>3. 5.>9. 5.>65. 3.>65.3 3.>5. 3.>77. 34.>58. 34.>66.3 36.3>9 36.3>9. 36.3>65. 8.3>63. 8.3>5. 8.3>35. 8.3>63. 8.3>35. 8.3>79. 94.>63.3 94.>5. 94.>33. 5.3>9. 5.3>9. 5.3>65. -6-34 -57-8 -6-4 -4-3 -5-6 -36-4 -5-44 -38-6 -6-4 -45-7 -65-39 -6-9 - -3-53 - -4-3 -7-45 -6-7 -7-53 -3 - - -4-37 -4-7 - - -9-3 -4-4 - - -5-43 D5-Nitrazepam (D5-NITRA) D4-KET D4-NORKET D4-BU D3-NORBU D3-MORP D3-COD D6-MAM D3-BE D5-AMPH D6-MDEA D5-MDA D5- D8-METH 5.63 4.3 4.9 5. 4.6.66 3.46 3.46 4.5 3.66 3.96 3.44 3.664 3.43 N.A. N.A. N.A. N.A. 87.>4. 87.>85. 87.>. 4.>9. 4.>4. 4.>. 8.>9. 8.>. 8.>83. 47.3>59. 47.3>4.3 47.3>. 47.3>83. 47.3>. 47.3>87. 89.>57. 89.>65. 89.>53. 33.>5.8 33.>64.9 33.>4.9 334.>64.9 334.>.9 334.>9.9 93.>7.3 93.>5. 93.>77. 4.3>4.3 4.3>9. 4.3>93. 4.3>66. 4.3>36. 4.3>8. 85.3>68.3 85.3>.3 85.3>38.3 99.3>65.3 99.3>7. 99.3>35. 58.3>93. 58.3>4.3 58.3>9. -6-36 -34-7 -5-5 -5 - -6-54 -4-43 -5-4 -4-43 -4-4 -67-45 -7-4 -7-3 - -9-55 -9-4 -7-3 - -6 - -3 - -3-6 - - -5-9 5

Performance of MRM-based Quantitative Method Linearity of the calibration curves with both IS method (4 analytes) and external standard method (4 analytes) were constructed using the standard samples prepared by pre-spiked in urine matrix are shown in Figure 4. The method parameters are summarized in Table 3. It can be seen that good linearity with R greater than.995 was obtained for the eighteen illicit drugs in the range from ng/ml to ng/ml in urine. Process Efficiency (P.E) was evaluated based on the peak area (external standard) or peak ratios (IS method) of pre-spiked samples and neat-spiked sample at all concentrations. The results shown in Table 3 indicate the P.E obtained for the 8 analytes are between 6~% except four analytes with higher values, Norbuprenorphine, Morphine, MAM, and Methadone. This could be due to interference from urine, which causes ion enhancement. Accuracy of the quantitation method was evaluated with pre-spiked standard samples at all concentrations. The results are shown in Table 3, which indicate that reliable quantitation accuracy was obtained, except Methadone at ng/ml with an accuracy of 3%. Specificity of the method for detection and confirmation of the eighteen illicit drugs was evaluated (Figure 5). The confirmation criteria for each target include quantifier MRM peak, its ratios with reference MRM transitions as well as retention time. 3..5.5.5.5.5.5 Conc. Ratio NIME / NITRA-d5 Conc. Ratio KET / KET-d4 Conc. Ratio NORKET / NORKET-d4 Conc. Ratio BU / BU-d4 Conc. Ratio NORBU / NORBU-d4 Conc. Ratio MORP / MORP-d3. 3 Area Area Area 3.5 5 Conc. Ratio COD / COD-d3 Conc. Ratio MAM / MAM-d6 Conc. Ratio BE / BE-d3 5. Conc. PCP 5. Conc. METQ 5. Conc. METD Area 5 4 3 5.5 5. Conc. PROP Conc. Ratio AMPH / AMPH-d5 Conc. Ratio MDEA / MDEA-d6 Conc. Ratio MDA / MDA-d5 Conc. Ratio / -d6 Conc. Ratio METH / METH-d8 Figure 4: Calibration curves of 4 illicit drugs with isotope-labelled internal standards and 4 illicit drugs with external standard in human urine on LCMS-84. Details are shown in Table 3. 6

Table 3: MRM quantitation method of eighteen illicit drugs Accuracy (%) Compd. ng/ml 5 ng/ml ng/ml R NIME KET NORKET BU NORBU MORP COD MAM BE PCP METQ METD AMPH MDEA MDA PROP METH 93.7 7.5 9.6 94.5.8 8.7 96. 89.6 9. 8.8 3. 9.7 84. 9..4. 83.7 3. 9.6 4..7 93.9 95.8.9 5. 98.8 3.8 9. 85.5 4. 7.7 3.8 95. 98.9 7.8 99.9.3 99.8 99.9.3. 99.9 99..8. 99.8 99.6.6 99.8 99.7 99.8. 99.7.9997.9983.9996.9998.999.9995.9999.9994.9999.9996.998.995.9996.9986.9996.9994.9999.9985 *The Cut Off is based on European Guidelines for Workplace Drug Testing in Urine *Cut Off ng/ml 5 3 3 5 5 5 5 3 Avg. P.E (%) 99. 7.9 6.5 8. 83. 6. 88.8 39.5.3 88.3.9 6.6 9.3 84.5 8.8 98.5. 84. 9 8 7 6 5 4 3 (A) 3. 4. 5. 6. min 9 8 7 6 5 4 3 (B) Morphine Amphetamine Methamphetamine Codeine MAM MDA MDEA Norketamine Benzoylecgonine (BE) Ketamine Norbuprenorphine 3. 4. 5. 6. min Buprenorphine Phencyclidine Propoxyphene (PCP) Methadone Methaqualone Nimetazepam Figure 5: Total MRM chromatograms of (A) blank urine and (B) spiked urine with eighteen illicit drugs ( ng/ml). 7

Conclusions A fully automated method of sample pretreatment and quantitation for eighteen illicit drugs in human urine was developed on a novel platform of CLAM-LC/MS/MS. The method performance was evaluated on the linearity, accuracy, specificity and process efficiency. Acknowledgement The authors thanks Dr Yao Yi Ju and Moy Hooi Yan for their valuable comments and discussion. The authors also thanks Health Science Authority (HSA), Analytical Toxicology Division for providing the analyte standards for this work. Disclaimer: The data and instruments presented in this Application News are intended for Research Use Only (RUO). Not for use in diagnostic procedures. First Edition: June, 7 Shimadzu Corporation, 7